Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al.

Eva Versteijne Jacob L van Dam Marc G Besselink Bas Groot Koerkamp Marjolein Y V Homs Johanna W Wilmink Casper H van Eijck Geertjan van Tienhoven

J Clin Oncol

Eva Versteijne, MD, PhD, Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Jacob L. van Dam, MD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marc G. Besselink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Bas Groot Koerkamp, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; Marjolein Y.V. Homs, MD, PhD, Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands; Johanna W. Wilmink, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Casper H. van Eijck, MD, PhD, Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, the Netherlands; and Geertjan van Tienhoven, MD, PhD, Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.

Published: October 2022